[
    [
        {
            "time": "2018-12-14",
            "original_text": "沪深上市公司18年12月14日晚间上市公司重要公告",
            "features": {
                "keywords": [
                    "沪深",
                    "上市公司",
                    "公告"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沪深上市公司18年12月14日晚间上市公司重要公告",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-12-14",
            "original_text": "今日（12月14日）沪深股通、港股通资金流向",
            "features": {
                "keywords": [
                    "沪深股通",
                    "港股通",
                    "资金流向"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "今日（12月14日）沪深股通、港股通资金流向",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 10,
                "Headline_Structure": 6,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-12-14",
            "original_text": "12月14日上市公司晚间公告速递",
            "features": {
                "keywords": [
                    "上市公司",
                    "公告",
                    "速递"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "12月14日上市公司晚间公告速递",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-12-14",
            "original_text": "恒瑞医药：注射用帕瑞昔布钠获药品注册批件",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "注射用帕瑞昔布钠",
                    "药品注册批件"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药：注射用帕瑞昔布钠获药品注册批件",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-12-14",
            "original_text": "285亿资金争夺20股：主力资金重点出击2股(名单)",
            "features": {
                "keywords": [
                    "285亿资金",
                    "主力资金",
                    "重点出击",
                    "名单"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "285亿资金争夺20股：主力资金重点出击2股(名单)",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-12-14",
            "original_text": "4+7城市药品集中采购成利器 仿制药进入薄利多销期",
            "features": {
                "keywords": [
                    "4+7城市",
                    "药品集中采购",
                    "仿制药",
                    "薄利多销"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "4+7城市药品集中采购成利器 仿制药进入薄利多销期",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 6,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-12-14",
            "original_text": "医药生物行业周报:仿制药迎变局,把握确定性投资机会",
            "features": {
                "keywords": [
                    "医药生物",
                    "仿制药",
                    "变局",
                    "投资机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报:仿制药迎变局,把握确定性投资机会",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]